XML 250 R173.htm IDEA: XBRL DOCUMENT
v3.26.1

List of subsidiaries (Details) | 12 Months Ended |
--- | --- | ---
Dec. 31, 2025 USD ($) | Dec. 31, 2024 USD ($) | Dec. 31, 2025 HKD ($) | Dec. 31, 2025 GBP (£) | Dec. 31, 2025 TWD ($)
Disclosure of subsidiaries [line items] |  |  |  |  |
Issued and fully paid share capital | $ 25,000 | $ 19,000 |  |  |
Prenetics Limited |  |  |  |  |
Disclosure of subsidiaries [line items] |  |  |  |  |
Issued and fully paid share capital |  |  | $ 415,276,716 |  |
Directly | 0.00% | 0.00% |  |  |
Indirectly | 100.00% | 100.00% |  |  |
Europa Partners Holdings, LLC (note 33) |  |  |  |  |
Disclosure of subsidiaries [line items] |  |  |  |  |
Issued and fully paid share capital | £ |  |  |  | £ 11.00 |
Directly | 0.00% | 0.00% |  |  |
Indirectly | 100.00% | 100.00% |  |  |
IM8 Group Holding Company |  |  |  |  |
Disclosure of subsidiaries [line items] |  |  |  |  |
Issued and fully paid share capital | $ 1 |  |  |  |
Directly | 100.00% | 100.00% |  |  |
Indirectly | 0.00% | 0.00% |  |  |
IM8 (US) LLC |  |  |  |  |
Disclosure of subsidiaries [line items] |  |  |  |  |
Directly | 100.00% | 100.00% |  |  |
Indirectly | 0.00% | 0.00% |  |  |
IM8 Limited |  |  |  |  |
Disclosure of subsidiaries [line items] |  |  |  |  |
Issued and fully paid share capital |  |  | 1 |  |
Directly | 100.00% | 100.00% |  |  |
Indirectly | 0.00% | 0.00% |  |  |
ACT Genomics Holdings Company Limited |  |  |  |  |
Disclosure of subsidiaries [line items] |  |  |  |  |
Issued and fully paid share capital | $ 16,713 |  |  |  |
Directly | 0.00% | 73.27% |  |  |
Indirectly | 0.00% | 0.00% |  |  |
ACT Genomics Co., Ltd. |  |  |  |  |
Disclosure of subsidiaries [line items] |  |  |  |  |
Issued and fully paid share capital |  |  |  |  | $ 455,080,000
Directly | 0.00% | 0.00% |  |  |
Indirectly | 0.00% | 73.21% |  |  |
ACT Genomics (Hong Kong) Limited |  |  |  |  |
Disclosure of subsidiaries [line items] |  |  |  |  |
Issued and fully paid share capital |  |  | 775,000 |  |
Directly | 0.00% | 0.00% |  |  |
Indirectly | 0.00% | 73.27% |  |  |
Sanomics Limited |  |  |  |  |
Disclosure of subsidiaries [line items] |  |  |  |  |
Issued and fully paid share capital |  |  | $ 500,000 |  |
Directly | 0.00% | 0.00% |  |  |
Indirectly | 0.00% | 73.27% |  |  |
MC Diagnostics Limited |  |  |  |  |
Disclosure of subsidiaries [line items] |  |  |  |  |
Issued and fully paid share capital | £ |  |  |  | £ 1,164 |
Directly | 0.00% | 0.00% |  |  |
Indirectly | 0.00% | 73.27% |  |  |

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The nominal value of capital issued. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph B9 -Subparagraph f -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B -URIDate 2025-03-27 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Note Expiry date 2027-01-01 -Name IAS -Number 1 -IssueDate 2025-01-01 -Paragraph 78 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_IssuedCapital
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2025-01-01 -Paragraph 17 -Subparagraph b -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b_iii&doctype=Standard -URIDate 2025-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2025-01-01 -Paragraph 16 -Subparagraph b -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b_iii&doctype=Standard -URIDate 2025-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2025-01-01 -Paragraph 19B -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_19B_c&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_ProportionOfOwnershipInterestInSubsidiary
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The proportion of the voting rights in a subsidiary held by the entity. [Refer: Total for all subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2025-01-01 -Paragraph 17 -Subparagraph b -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b_iii&doctype=Standard -URIDate 2025-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2025-01-01 -Paragraph 16 -Subparagraph b -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b_iii&doctype=Standard -URIDate 2025-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2025-01-01 -Paragraph 19B -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_19B_c&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_ProportionOfVotingPowerHeldInSubsidiary
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=pre_PreneticsLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=pre_EuropaPartnersHoldingsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=pre_IM8GroupHoldingCompayMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=pre_IM8USLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=pre_IM8LimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=pre_ActGenomicsHoldingsCompanyLimitedACTGenomicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=pre_ActGenomicsCo.Ltd.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=pre_ActGenomicsHongKongLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=pre_SanomicsLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=pre_MCDiagnosticsLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |